Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Orloff · SciRah

Researcher profile · Semantic Scholar

D. Orloff

Share profile

D. Orloff — researcher profile on SciRah

h-index: 19
Works: 39
Citations: 7,253

Most-cited papers

National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
S. Grundy, D. Becker, L. Clark, R. Cooper +29 more
20155,407 citations
Semantic Scholar
Family of disulphide-linked dimers containing the ζ and η chains of the T-cell receptor and the γ chain of Fc receptors
D. Orloff, C. Ra, S. Frank, R. Klausner +1 more
1990Nature224 citations
Semantic Scholar
A regulated RNA binding protein also possesses aconitase activity.
S. Kaptain, W. Downey, Careen K. Tang, C. Philpott +5 more
1991Proceedings of the National Academy of Sciences of the United States of America193 citations Open access
Semantic Scholar
Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: distinction from the molecular CD3 complex.
A. Weissman, D. Hou, D. Orloff, W. Modi +3 more
1988Proceedings of the National Academy of Sciences of the United States of America162 citations Open access
Semantic Scholar
Effects of damage to the suprachiasmatic area of the anterior hypothalamus on the daily melatonin and cortisol rhythms in the rhesus monkey
S. Reppert, M. Perlow, Leslie G. Ungerleider, M. Mishkin +4 more
1981Journal of Neuroscience162 citations Open access
Semantic Scholar
Vascular Biomarkers and Surrogates in Cardiovascular Disease
J. Tardif, T. Heinonen, D. Orloff, P. Libby
2006Circulation155 citations
Semantic Scholar
Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.
P. Thompson, D. Macdougall, R. Newton, J. Margulies +4 more
2016Journal of Clinical Lipidology130 citations Open access
Semantic Scholar
Role of the zeta chain in the expression of the T cell antigen receptor: genetic reconstitution studies.
Allan M. Weissman, Stuart J. Frank, D. Orloff, M. Merćep +2 more
1989EMBO Journal112 citations Open access
Semantic Scholar
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
K. Maki, D. Orloff, S. Nicholls, Richard L. Dunbar +5 more
2013Clinical Therapeutics111 citations
Semantic Scholar
Structural mutations of the T cell receptor zeta chain and its role in T cell activation.
Stuart J. Frank, B. Niklinska, D. Orloff, M. Merćep +2 more
1990Science108 citations
Semantic Scholar
Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.
R. Eastman, Richard E. Carson, D. Orloff, C. Cochran +6 more
1992Journal of Clinical Investigation77 citations Open access
Semantic Scholar
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
J. Revkin, C. Shear, H. Pouleur, S. Ryder +1 more
2007Pharmacological Reviews76 citations
Semantic Scholar
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
Richard L. Dunbar, S. Nicholls, K. Maki, E. Roth +5 more
2015Lipids in Health and Disease50 citations Open access
Semantic Scholar
Biochemical characterization of the eta chain of the T-cell receptor. A unique subunit related to zeta.
D. Orloff, Stuart J. Frank, F. Robey, Allan M. Weissman +1 more
1989Journal of Biological Chemistry50 citations Open access
Semantic Scholar
An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein
T. Rouault, D. Haile, W. Downey, C. Philpott +7 more
1992Biometals38 citations
Semantic Scholar
The effects of environmental lighting on the daily melatonin rhythm in primate cerebrospinal fluid.
S. Reppert, M. Perlow, L. Tamarkin, D. Orloff +1 more
1981Brain Research35 citations
Semantic Scholar
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
H. Bays, J. Hallén, R. Vige, D. Fraser +4 more
2016Journal of Clinical Lipidology30 citations
Semantic Scholar
Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors.
D. Orloff, C. Ra, S. Frank, R. Klausner +1 more
1990Nature29 citations
Semantic Scholar
Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach.
D. Orloff
2005American Journal of Cardiology25 citations
Semantic Scholar
Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development.
D. Orloff
2001American Journal of Cardiology15 citations
Semantic Scholar
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia
J. Kastelein, J. Hallén, R. Vige, D. Fraser +4 more
2016The Cardiology13 citations Open access
Semantic Scholar
Homocysteine as a predictive factor for hip fracture in older persons.
S. Ellenberg, D. Orloff, R. Temple
2004New England Journal of Medicine12 citations
Semantic Scholar
Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
J. Isaacsohn, A. Troendle, D. Orloff
2004American Journal of Cardiology11 citations
Semantic Scholar
The impact of the National Cholesterol Education Program Adult Treatment Panel III guidelines on drug development.
J. Isaacsohn, D. Black, A. Troendle, D. Orloff
2002American Journal of Cardiology9 citations
Semantic Scholar
ETC-1002 LOWERS LDL-C MORE THAN EZETIMIBE IN PATIENTS WITH HYPERCHOLESTEROLEMIA WITH OR WITHOUT STATIN INTOLERANCE AND HAS A SIMILAR SAFETY AND TOLERABILITY PROFILE
P. Thompson, C. Ballantyne, J. Mckenney, D. Orloff +4 more
20155 citations Open access
Semantic Scholar
Regulatory considerations in the development of high-density lipoprotein therapies.
D. Orloff
2007American Journal of Cardiology5 citations
Semantic Scholar
Update on the U.S. Food and Drug Administration regulatory approach to over-the-counter cholesterol-lowering drugs.
D. Orloff
1998American Journal of Cardiology3 citations
Semantic Scholar
A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL)
K. Maki, D. Orloff, S. Nicholls, Richard L. Dunbar +5 more
20132 citations Open access
Semantic Scholar
Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
D. Orloff, M. Blazing, C. O'Connor
1999American Heart Journal1 citations
Semantic Scholar
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
Richard L. Dunbar, S. Nicholls, K. Maki, E. Roth +5 more
2015Lipids in Health and Disease0 citations Open access
Semantic Scholar
Epanova Lowers Apolipoprotein C-III and Increases LDL-Particle Size in Statin-Treated Patients With Mild Hypertriglyceridemia
K. Maki, D. Orloff, S. Nicholls, Richard L. Dunbar +4 more
20130 citations
Semantic Scholar
Mo-S6:4 The place for vascular imaging data in the evidence package for new drugs for atherosclerosis: Regulatory principles
D. Orloff
20060 citations
Semantic Scholar
Proceedings of the nineteenth annual symposium: advances in cardiovascular pharmacology: protocol design and methodology. the U.S. Regulatory Process. May 3, 4, 5, 2000, Washington, D.C.
J. Borer, R. Fenichel, N. Stockbridge, D. Throckmorton +7 more
2001American Journal of Therapeutics0 citations
Semantic Scholar
Anti-lipid trial endpoints.
D. Orloff
1999American Journal of Therapeutics0 citations
Semantic Scholar
Guidelines for approval of anti-obesity drugs affecting atherosclerosis and/or lipids. Discussion
J. W. Anderson, R. Ziegler, D. Orloff, J. Larosa
19980 citations
Semantic Scholar
Section III: Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism? Discussion
R. Paoletti, James Shepherd, A. Olsson, F. Sacks +3 more
19980 citations
Semantic Scholar
Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
J. Shepherd, Anders G. Olsson, F. Sacks, D. Black +2 more
1998American Journal of Cardiology0 citations
Semantic Scholar
Inclusion of lipoprotein subfractions among efficacy parameters. Discussion
H. Superko, D. Orloff
19980 citations
Semantic Scholar
Molecular cloning and chromosomal localization of the human T-cell receptor ; chain: Distinction from the molecular CD3 complex (cDNA/receptor
A. Weissman, D. Hou, D. Orloff, William S. MODIt +3 more
0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Klausner×9
Invite
R. Klausner — researcher profile on SciRah
K. Maki×5
Invite
K. Maki — researcher profile on SciRah
S. Nicholls×5
Invite
S. Nicholls — researcher profile on SciRah
Richard L. Dunbar×5
Invite
Richard L. Dunbar — researcher profile on SciRah

×5

Invite

E. Roth — researcher profile on SciRah

Judith Johnson×5

Invite

Judith Johnson — researcher profile on SciRah

Invite

D. Kling — researcher profile on SciRah

Invite

D. Curcio — researcher profile on SciRah

Invite

M. Davidson — researcher profile on SciRah

Invite

J. Mckenney — researcher profile on SciRah

Stuart J. Frank×3

Invite

Stuart J. Frank — researcher profile on SciRah

Invite

D. Black — researcher profile on SciRah